Interim Findings on Skin Health
Interim results from two ongoing investigator-initiated trials reveal that Sculptra and Restylane are effective in addressing aesthetic changes associated with menopause and weight loss medications. Announcements made on 9 April 2026 confirm these findings.
Dr. Andreas Nikolis, study lead investigator, emphasised the specific skin changes in menopause. “Menopause is associated with a distinct and often under-recognised set of skin changes, including dryness, barrier dysfunction, and progressive declines in skin quality,” he stated.
The trials, supported by Galderma, demonstrated significant improvements in skin hydration and barrier function in menopausal women using Restylane Skinboosters and Sculptra. Noticeable gains in hydration were observed when Restylane was applied first, highlighting the importance of proper treatment sequencing.
Conducted over a nine-month period, Dr. Nikolis’s study involved both the face and décolletage, showing progressive improvements in skin quality. The combination treatments provided meaningful hydration, a critical need for perimenopausal skin health.
Weight Loss and Skin Changes
Another trial led by Dr. Sabrina Fabi showed alterations in the cellular composition of adipose tissue in patients experiencing aesthetic changes due to medication-driven weight loss. The study found a significant reduction in adipose-derived stem cells, underscoring the importance of regenerative treatments like Sculptra to address volume loss beyond weight reduction alone.
Galderma’s commitment to supporting independent research is evident in these trials. Their goal is to deliver holistic, individualized, and science-led solutions that address growing patient needs such as aesthetic changes related to menopause and medication-driven weight loss.
The new findings highlight the versatility of Galderma’s products, including the hyaluronic acid injectable Restylane range and Sculptra, the first proven regenerative biostimulator. They effectively address aesthetic changes for both the face and body.
The two IITs were designed and executed by Dr. Andreas Nikolis and Dr. Sabrina Fabi respectively. Galderma proudly supported the IITs as part of its long-standing commitment to understanding patients’ evolving needs and delivering the best solutions for optimal patient outcomes.
Further results from these trials are expected later in the year, providing more insights into effective treatment sequences for improving skin health in these patient groups. The studies continue to emphasise the importance of individualized treatment plans tailored to each patient’s unique needs.
Galderma’s ongoing support of these trials demonstrates their dedication to advancing dermatological solutions. The trials, which include the first-of-its-kind study on menopausal skin, are pivotal in shaping future treatment protocols.
Last updated: 9 April 2026, 7:04 pm
